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12 Synopsis 
13 Objective: To use illness severity scores to evaluate the appropriateness of antibiotic prescribing in 
14 United Kingdom general practice
15 Methods: To describe variations in practice prescribing rates, taking account of illness severity. We 
16 used three scores in three studies to measure severity: ‘FeverPAIN’ in an adult acute sore throat 
17 cohort (n=12,829), the ‘3C score’ in an adult acute lower respiratory infection cohort (n=28,883), and 
18 the STARWAVe score in an acute cough and respiratory infection children’s cohort (n=8,394). We 
19 calculated median odds ratios to quantify practice-level variation in prescribing rates, adjusted for 
20 illness severity. 
21 Results: There was substantial variability in practice prescribing rates (ranges 0%-97%, 7%-100%, and 
22 0%-75% in the three cohorts respectively). There was evidence that higher prescribing practices saw 
23 a higher proportion of unwell patients. At the individual level, more unwell patients were more likely 
24 to receive a prescription but prescribing levels for those with low scores were still high.  The median 
25 odds ratio was 2.6 (95% CrI2.3-2.9) in the sore throat dataset, 2.9 (95% CrI 2.6-3.2) in the adult 
26 cough dataset and 2.1 (95% CrI 1.8-2.4)  in the children’s cough dataset. 
27 Conclusion: Higher prescribing practices may see more unwell patients with high illness severity 
28 scores, but the differences in scores accounts for a minority of between practice prescribing 
29 variation. There is likely to be scope for further reductions in antibiotic prescribing among patients 
30 with low illness severity scores.  Further research is needed to explore the additional factors which 
31 account for variation in prescribing levels.
32
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34 Introduction
35 Acute uncomplicated respiratory tract infections are the commonest acute illness managed in 
36 primary care among developed countries and substantial numbers still receive antibiotics1, 2. 
37 However, systematic reviews have suggested that antibiotics confer limited symptomatic benefit 
38 for acute bronchitis3 and sore throat4.  Moreover prescribing promotes antibiotic resistance - 
39 which is dominated by primary care prescribing of antibiotics5 and tackling antibiotic resistance is 
40 an international priority.  
41 Analysis of routine prescribing data reveals wide variation in antibiotic prescribing rates between 
42 practices. In one large United Kingdom (UK) study using data from the Clinical Practice 
43 Research Datalink (CPRD),the median general practice prescribed antibiotics at 54% of 
44 respiratory tract infection (RTI) consultations, ranging from 39-69% in the lowest to highest decile 
45 of prescribing1. The rates observed in the The Health Improvement Network (THIN) database 
46 between 2013 and 2015 for acute bronchitis consultations suggested that 82% resulted in an 
47 antibiotic prescription and for sore throat 59% of consultations resulted in a prescription.6  Whilst 
48 antibiotics are clearly appropriate and necessary in some cases, modelling suggests that the 
49 ideal prescribing rates for these conditions are much lower – 13% for both conditions.6  
50 A recent paper exploring data from UK national prescribing datasets showed that although 
51 antibiotic prescribing rates have fallen since 2010, there is considerable geographic variation 7.  
52 Higher prescribing practices tended to have a higher proportion of patients >65 years, a higher 
53 proportion of patients <18 years, a higher proportion of patients with long-term conditions, a 
54 higher level of deprivation and were more likely to be rural.   The authors suggest that were all 
55 practices to prescribe at the lowest decile rate from 2017, 10.8 million fewer prescriptions could 
56 have been issued, a reduction of 34%.  
57 Research in the THIN database also explored variability in antibiotic prescribing and found that a 
58 model including consultation rates, comorbidities, steroid and immunosuppressive use and 
59 demographics still could not explain the considerable amount of the between-practice variation.8 
60 A further study in national prescribing data similarly found that between-practice variation in 
61 prescribing rates could not be explained by legimate medical reasons, such as different 
62 prevalence of smoking, comorbidities,or deprivation. 9 
63 At the individual level, the decision to prescribe is a complex one10.  General Practitioners (GPs) 
64 prescribe for a wide range of reasons, including psychosocial aspects11. The current guidelines 
65 suggest an immediate prescription for those at higher risk of complications due to comorbid 
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66 conditions12.  Many also prescribe for to reduce the risk of complications even though 
67 complications  are rare,  In sore throat,  and the number needed to treat to reduce the risk of 
68 complications such as quinsy, impetigo, cellulitis, otitis media, and sinusitis,is nearly 200 to 
69 reduce the complication risk13. In one interview study, GPs spoke of uncertainty about which 
70 patients were at most risk and would benefit most from an antibiotic prescription, and many 
71 acknowledged they had a different threshold for prescribing to patients with comorbidity or lower 
72 socioeconomic status11.  
73 Routine data cannot tell us whether the observed wide range in prescribing might be attributable 
74 to patient characteristics (case mix) or practice characteristics or culture.  It may not be 
75 appropriate for all practices to aim to be prescribing in line with the lowest decile if, for example, 
76 some practices tend to see a larger proportion of patients who present with signs and symptoms 
77 that suggest they may benefit from antibiotics.   
78 As electronic health record data does not provide information on the severity of infection, there is 
79 an advantage to instead exploring this question using cohort data.  This paper reports a 
80 secondary analysis of three large primary care cohorts investigating acute respiratory infections, 
81 one in acute sore throat13 and two in acute cough14, 15.  These datasets included clinical data at 
82 the index consultation, thereby enabling further exploration of the relationship between patient 




87 This was a secondary analysis of three large cohort studies.  These cohorts were constructed to 
88 develop prediction rules to guide antibiotic treatment in a primary care context.  Participating GPs 
89 were asked to document their normal prescribing practice and were aware that these practices 
90 would help the study teams to develop clinical prediction rules, but were not aware of which 
91 predictors would ultimately be included in these rules and were instructed to follow their normal 
92 practice with respect to antibiotic prescribing.  
93 The DESCARTE study (Decision rule for the Symptoms and Complications of Acute Red Throat 
94 in Everyday practice)13 was prospective cohort study comprising 14,610 adults aged ≥16 years 
95 presenting with acute sore throat (≤2 weeks’ duration).  Patients were recruited from 616 
96 practices in England and Wales between November 2006 and June 2009
97 The 3C study (cough complication cohort)14  was a prospective cohort of 28 883 patients with 
98 lower respiratory tract infection recruited from 522 UK practices between 2009 and 2013.  
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99 The TARGET study15 was a prospective cohort of 8394 children aged between 3 months and 16 
100 years presenting with acute cough and respiratory tract infection recruited from 247 general 
101 practices in England between July 2011 and June 2013.  
102 In all three studies, clinicians completed a case report form detailing clinical signs and symptoms 
103 at the initial consultation.  In the 3C and TARGET studies, patient-level deprivation was 
104 measured by matching postcode to IMD 2010 data.16  In the DESCARTE cohort, this information 
105 was not available at the individual level and the practice postal code was instead used to 
106 determine the IMD 2010 score.  
107 Statistical methods
108 Descriptive statistics and graphs were used to explore whether participating practices with higher 
109 prescribing rates saw more patients who were likely to benefit from an antibiotic, as well as to 
110 summarised whether these patients were more likely to actually receive an antibiotic prescription.  
111 For the DESCARTE sore throat cohort, the FeverPAIN score includes fever during the previous 
112 24 hours, pus on tonsils, attendance within 3 days of onset, severely inflamed tonsils and no 
113 cough or coryza17.  In the UK, National Institute for Health and Clinical Excellence (NICE) 
114 guidelines suggest that those with a score of 0 or 1 might be unlikely to benefit from antibiotics 
115 whilst a score of 4 higher should be considered for an antibiotic prescription18.  
116 The Centor score is also available in the DESCARTE cohort and includes absence of cough, 
117 swollen and tender anterior cervical nodes, temperature > 38°C, tonsillar exudates, age.19.  NICE 
118 guidance suggests that patients with a Centor score of 0, 1 or 2 are unlikely to benefit from 
119 antibiotics whereas those with a score of 3 or 4 should be considered for an immediate or 
120 delayed antibiotic 18.  Results for all analyses using the Centor score are given in the 
121 supplementary material (see Figure S1 and Table S1).  
122 For the 3C cough cohort in adults, this was based on the risk of pneumonia, defined as having 
123 one of temperature >37.8°C, crackles on auscultation, oxygen saturation <95%, and pulse 
124 >100·min).20.  Having at least one of these symptoms was associated with an increased risk of 
125 pneumonia on x-ray and therefore these patients should be considered for an immediate 
126 antibiotic.  
127 For the TARGET cohort, children presenting with cough, we used the STARWAVe clinical rule.  
128 STARWAVe is comprised of short illness (≤3 days), temperature>37.8°C; age (<24 months); 
129 recession; wheeze; asthma; and vomiting15.  Scores of 0/1 indicate very low risk of 
130 hospitalisation in the following 30 days and these children are unlikely to benefit from antibiotics.  
131 A score of 2-3 represents “normal” risk and again a strategy of no prescribing or delayed 
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132 prescribing may be appropriate.  Children with a score of 4 or more are considered high risk and 
133 should be considered for an immediate antibiotic prescription. 
134 As practices recruiting few patients may have recruited selectively and provided limited 
135 participants for analysis we only included all practices which had recruited at least 10 patients 
136 into the study.  We also exclude any patients who were referred to hospital on the same day as 
137 their consultation.  In these patients it is less likely that a GP would issue a prescription, leaving 
138 the prescribing decision to the hospital clinicians.  And we excluded those who received a 
139 delayed prescription.  These represented too small a proportion of each cohort to explore the 
140 variability between practices.  
141 The probability of receiving an antibiotic prescription was modelled in a multi-level logistic 
142 regression model.  The model included as independent variables FeverPAIN score for sore 
143 throad (or the 3C score for pneumonia risk or STARWAVe score for risk in children), age, 
144 gender, deprivation score and co-morbidity.  All variables were included in the way in which they 
145 had been collected in the original studies.  Age was a continuous variable modelled linearly, 
146 deprivation used IMD quintiles and comorbidity defined as the presence of at least one comorbid 
147 condition.  Practice was included as a random effect.  We then calculated the median odds ratio 
148 (MOR) and 95% credible interval.  This transforms the variability between practices into an odds 
149 ratio scale.21, 22  It describes the probability that two randomly selected practices would treat an 
150 identical patient in the same way It describes the increase in odds of receiving a prescription as a 
151 patient moves from a lower-risk cluster to a higher-risk cluster.  . A MOR of 1.00 would indicate no 
152 variability between practices, a significant score >1 would suggest that some practices are more 
153 likely to treat than others, irrespective of patient severity.
154
155 To obtain the MOR and credible interval, we ran the model using MCMC estimation via the 
156 “runmlwin” command22 in Stata v14.0.  This directly computes the 95% credible interval for the 
157 MOR using the posterior distribution of the area variance.  
158
159 We also calculated the proportion of the variance explained by the variables in the model.    
160 Whilst this value, usually denoted R2 is automatically available for linear regression, for multi-
161 level logistic regression, it must be calculated from the residual variances.  We therefore 
162 calculated the R2 value as:  where Varnull is the residual variance of a null model 𝑅2 =
𝑉𝑎𝑟𝑛𝑢𝑙𝑙 ― 𝑉𝑎𝑟𝑓𝑢𝑙𝑙
𝑉𝑎𝑟𝑛𝑢𝑙𝑙
163 with only the intercept and practice-level random effects, and Varmodel is the residual variance of 
164 a model that the independent variables and the practice-level random effect.  We have followed 
165 the approach set out in Weinmayr et al 23 and calculated the relative reduction in the rescaled tau 
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166 parameter compared to the null model using the Stata do-file provided as supplementary material 
167 to their paper.  
168 It is possible that differences in prescribing rates at the practice level may reflect differences not 
169 in routine prescribing but in the way in which GPs recruited into the cohort studies.  Although 
170 GPs were asked to recruit all eligible patients with sore throat/cough, it is possible that some 
171 might have opted to only include those patients to whom they planned to prescribe.  If different 
172 GPs interpreted the inclusion criteria in different ways, we would see a wider range of prescribing 
173 rates and more variability between practices than exists in routine practice.  To test this 
174 assumption, we matched practices from the 3C cohort to their overall antibiotic prescribing rates 
175 based on Specific Therapeutic group Age-sex weightings Related Prescribing Units (STAR-PU) 
176 from 1 January to 31 December 2015 available at the practice level from the NHS England 
177 Antibiotic Quality Monitoring Dashboard24.   Due to the way in which the data was collected it 
178 was not possible to do this for the DESCARTE or TARGET cohorts.  We hypothesised that a 
179 high correlation between the prescribing rate in the cohort and the prescribing rate in the national 
180 data would indicate that practices had not selectively recruited into the cohort but that the 
181 prescribing rate in the data was reflective of normal practice.  
182 Results
183 Study population
184 After excluding those practices that recruited less than 10 participants to the studies, those 
185 hospitalised on the day and those who received a delayed prescription, there were 9,007 
186 participants in the DESCARTE cohort, 24,320 in the 3C cohort and 7,252 in the TARGET cohort. 
187
188 The datasets represented somewhat different populations, which reflects both the illness of 
189 interest and their target populations.  The DESCARTE sore throat cohort was 67.4% female with 
190 an average age of 33.64 years.  Most participants had been unwell for around 4 days prior to 
191 consultation.  The 3C cough cohort was 59.2% female and had a higher average age of 51.87 
192 years.  Most participants had been ill for slightly longer – 7 days =  prior to their initial 
193 consultation.  The TARGET cohort recruited only children with acute and this is reflected in the 
194 lower average age of 3.81 years and a somewhat shorter duration prior to consultation of 5 days, 
195 compared to the 7days for the adult 3C cough cohort.   
196
197 The median IMD rank was 15,780 (IQR 6636,24189) in the DESCARTE data and 16,590 (IQR 
198 8393, 25311)  in the TARGET data.  IMD ranks range from 1 in the most deprived Lower Super 
199 Ouput Area to 32,844 in the least deprived area, suggesting that out population was recruited from 
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200 practices with a range of deprivation levels25.  This data was not available for 3C, where data was 
201 only recorded in deprivation quintiles.  
202
203 Variation in prescribing rates at the practice level
204 There was substantial variability in prescribing rates by practice (Table 1). In the sore throat 
205 dataset, the range was 0%-97% of patients receiving an immediate antibiotic prescription, with a 
206 median rate of 46%.  In the 3C dataset the range was 7%-100%, with a median rate of 62% and 
207 in TARGET the range was 0%-75% with a slightly lower median rate of 22%.  
208 The correlation between the practices in the 3C dataset and their antibiotic prescribing rates in 
209 the national data was 0.84 suggesting that high prescribers in the cohort were very likely to be 
210 high prescribers in the national data.  Therefore it is likely that these wide ranges of prescribing 
211 rates are indicative of true differences between practices and are not an artefact of their 
212 interpretation of the study recruitment procedures.  
213 There was some evidence in all 3 datasets that those practices with higher prescribing rates saw 
214 more patients with higher severity/prognostic scores.  There was a moderate correlation of 0.42 
215 for the FeverPAIN score and prescribing rate, in the sore throat dataset.  In the adult cough 
216 dataset, the correlation was 0.44 between pneumonia risk and the prescribing rate.  The 
217 correlation was lower in children at only 0.20.  If practices were divided into quartiles by 
218 prescribing rate then, as Figures 1-3 illustrate, there is a gradient, with the higher prescribing 
219 quartile tending to see more patients who were likely to benefit from a prescription.  
220
221 Prescribing rates at the individual patient level
222 At the individual level, patients who were more unwell are more likely to receive a prescription 
223 with 96.9% of those with a FeverPAIN score of 4+ receiving an immediate antibiotic (Table 2).  
224 The proportion was similarly high for those with a higher risk of pneumonia, with 91.7% receiving 
225 an immediate antibiotic.  But prescribing levels for those will low risk scores was also high; –
226 38.7% of those with a FeverPAIN score of 0/1 received a prescription and 43.4% of those at low 
227 risk for pneumonia. 
228 In children there seemed to be more uncertainty around prescribing, with only 66.2% of children 
229 in the highest risk group receiving a prescription.  However, as in the adult datasets, a high 
230 proportion – 26.4% of those at very low risk of future admission – still received a prescription.   
231 Median Odds ratios
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232 The median odds ratio was high in all the datasets.  In the sore throat dataset, the MOR 2.49 
233 (95% credible interval 2.21, 2.85) when the model included FeverPAIN score, age, sex, 
234 deprivation and comorbidity.  These individual level variables only reduced the rescaled tau2 
235 parameter by 3.2%, suggesting that the proportion of variability between practicesaccounted for 
236 12.6% of the variance in the probability of receiving a prescription explained by the individual 
237 level variables is low.  The MOR was 2.86 (95% credible interval 2.60, 3.17) in the adults cough 
238 dataset and the independent variables accounted reduced the the rescaled tau2 forby 0.8% of 
239 the variability.  And in the children’s cough dataset, the MOR was 2.06 (95% credible interval 
240 1.82, 2.36) and the individual level variables accounted forreduced the rescaled tau2  by1.93.6% 
241 of the variability.  This suggests that even after controlling for risk score, age, sex, deprivation 
242 and comorbidity, an ide tical patient attending 2 randomly selected practices would be much 
243 more likely to receive antibiotics in some practices than in others and that there is substantial 
244 variability which is not explained by the variables in the model.  
245
246 Discussion
247 Summary of main findings
248 There was a large range in prescribing in this observational data set in line with expectations 
249 from analysis of routine data. In adults, antibiotics were targeted to those who were more unwell 
250 however there was wide variation in prescribing to less unwell patients.  In children, the pattern 
251 was similar but there seemed to be more uncertainty in the higher risk children as well, with only 
252 66% receiving an immediate prescription.
253 Whilst some of that variation in prescribing can be attributed to illness severity (case mix) there 
254 was evidence that there was considerable residual variability, attributable to practice and 
255 physician factors.  
256 Findings in context of existing literature  
257 Our study is consistent with the findings of other work in the United Kingdom and the United 
258 States which has shown high levels of variability in prescribing between practices.  Palin et al. 
259 explored variability in antibiotic prescribing at the GP practice level in the CPRD database over 
260 time.26  They also found considerable between-practice variability, with some practices 
261 prescribing 10% of the time and others up to 70% of the time.  Patient characteristics did not 
262 completely explain this variability, nor did changes in prescribing guidelines over time.  Several 
263 studies have suggested that age, region, race and comorbid conditions are associated with 
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264 antibiotic prescribing.7, 27-29.  But all these studies all concluded, as we did, that there was 
265 considerable variability between practices that could not be explained by these factors alone and 
266 that there remained considerable opportunity for reducing inappropriate prescriptions
267 There is also evidence that high levels of antibiotic prescribing are associated with high levels of 
268 antidepressant prescribing30.  And recent studies have shown that the levels of steroid and 
269 immunosuppressive drug prescribing8, and the levels of prescribing of other medications 
270 including non-opioid painkillers and benzodiazepines 31 were stronger predictors of antibiotic 
271 prescribing rates than variables such as comobidities or deprivation.   and iIt is possible that 
272 some GPs and/or practices have a lower threshold for prescribing than others. Further work may 
273 be needed to address this propensity to prescribe, given the evidence from our dataset that it 
274 may not be driven by patient-level factors or the likelihood of the prescription providing a benefit.  
275 Strengths/limitations
276 Data is available for three large cohorts with prospective collection of baseline signs/symptoms 
277 enabling an analysis including illness severity.  Whilst other studies have been able to explore 
278 variability in prescribing in routine data, baseline signs and symptoms are often poorly recorded.  
279 It is therefore a strength of this study that we were able to look at the potential of these factors to 
280 explain variability in prescribing across three large datasets.  We were also able to control for 
281 the baseline severity of the illness which may be a potential source of residual confounding by 
282 indication in electronic health record studies.  
283
284 We cannot exclude selection bias where GPs may have chosen selected patients for entry into 
285 the study with a potential impact on the attributed prescribing rates.  However all three  cohorts 
286 revealed similar findings and for 3Cs, we were able to compare practice level prescribing in the 
287 cohort to national antibiotic prescribing data from 2015; the correlation with national prescribing 
288 rates in the cohort study was high (r=0.84).  We cannot exclude the possibility that high 
289 prescribing practices systematically attribute symptom scores with higher severity hence 
290 explaining the greater illness severity observed in these sites but we would have hypothesised 
291 that this would have reduced the variability as higher prescribing would be better explained by 
292 higher severity scores.  
293 We classified practices into quartiles based on their prescribing rates.  However, these quartiles 
294 are based on the distribution in the data.  Therefore “low” and “high” prescribing practices are 
295 designations relative to other practices in the dataset, regardless of whether their rates of 
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296 prescribing were high or low in real terms or whether their prescribing rates were appropriate to 
297 the patients they saw.  
298 The cohorts collected between 2006 and 2013.  It is possible that over time prescribing generally 
299 has changed and/or that the publication of the rules derived from these datasets may have 
300 improved the appropriateness of prescribing.  For example, FeverPAIN is now included in the 
301 NICE guidelines but this change occurred during the time that the sore throat cohort was 
302 collecting data.   Whilst it is possible that prescribing has moved on from the picture provided by 
303 this data, as noted above the results in this paper are consistent with other recent studies using 
304 routine data which have observed similar variability in prescribing.  
305 We could only explore the relationship between those characteristics that were measured in the 
306 cohort studies and prescribing.  It is possible that better recording of the data, e.g. more data on 
307 comorbid conditions or household deprivation, might have helped to explain a larger proportion of 
308 the variance.  However, as discussed below, other studies have found a similar results.  
309 Important factors such as the experience of the GP, social factors or whether or not the patient 
310 requested an antibiotic were not recorded and may have helped to explain some of the variation 
311 observed.  Whilst there is robust evidence for lack of benefit of antibiotics for symptom relief in 
312 adults with sore throat and bronchitis the same is not the case in children where are no 
313 substantive studies of antibiotics for Lower Respiratory Tract Infection (LRTI). We used the newly 
314 developed STARWAVE tool to attribute prescribing benefit, however this was developed to 
315 predict children at risk of admission with RTI and we do not know if antibiotics modify this risk or 
316 if other groups of children might potentially benefit from antibiotics. 
317
318 Implications for clinical practice and further research
319 Higher prescribing practices did see more severely unwell patients and therefore caution should 
320 be exercised in targeting those practices specifically.  Antibiotics are appropriate and even 
321 necessary for some patients and whilst there may be ideal levels of prescribing overall for 
322 different conditions the differences observed in the patient populations at different practices in 
323 this study and others suggest that setting a the same practice-level target for all practices is 
324 unlikely to be appropriate 6, 9, 27.  
325 The ‘low hanging fruit’ for antibiotic stewardship is those patients at low risk of serious infection 
326 or who are not very unwell.  Instead of targeting practices to reduce prescribing, encouraging 
327 practitioners to use clinical scores to limit prescribing for patients with less severe illness could 
328 yield substantial reductions in antibiotic prescriptions.  For acute sore throat and LRTI the overall 
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329 risk of complications is low.  Whilst the use of clinical scores may not predict the likelihood of 
330 future complications, such scores are a useful guide to prescribing when coupled with clinical 
331 judgement –FeverPAIN, for example, whilst not a predictor of complications32 but is a good 
332 predictor of Strep infection and hence need for antibiotics17.  Similarly the 3C score was 
333 developed to predict pneumonia, which would usually be treated with antibiotics. The PPV of 
334 having one of these signs was 20%, which again may represent a suitable population for 
335 targeted prescribing21. The STARWAVe score helped to identify the 11.8% of children in the 
336 highest risk category who were at high risk of future admission.  Whilst not all would have 
337 benefited from a prescription, this group might be the most suitable to targeted prescribing”15.
338 Further guidance on how to recognise children at high risk of adverse outcome may also help to 
339 ensure that antibiotics are targeted more appropriately in this population.  
340 Whilst this study has highlighted that illness severity scores and individual characteristics explain 
341 very little of the variability in practice-level prescribing, further research is needed to explore 
342 which factors do help to explain these observed differences.  This may help to better target 
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439 TABLES AND FIGURES




Female 6071 (67.4%) 14,392 (59.2%)  3484/7252 (48.0%)
Mean age in years (s.d.) 33.84 (14.61) 51.87 (17.98) 3.81 (3.72) 
Mean temperature °C 
(s.d.)
36.83 (0.70) 36.73 (0.66) 36.98 (0.77) 
Median days of illness 
prior to consultation 
(IQR)
4 (2,6) 7 (5,14) 5 (3,10)
Practice characteristics
Number of practices 
recruiting 10+ patients
222 363 135








Page 13 of 18
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
scoreMedian Index of 
Multiple Deprivation 
rank




prescribing rate  (LQ, 
UQ)
46% (37%, 61%) 62% (47%, 75%) 22% (15%, 32%)
441
442
443 Figure 1. FeverPAIN score by prescribing quartile
444


















446 Figure 2. Pneumonia risk by prescribing quartile – 3C cohort
447
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455 Table 2.  Proportion receiving immediate antibiotics by FeverPAIN, pneumonia risk and 
456 STARWAVe scores
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FeverPAIN score Pneumonia score STARWAVe scoreReceived 
immediate 
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1 Supplementary Data
2 The results for Centor were similar to those for FeverPAIN, with higher prescribing practices 
3 seeing a higher proportion of unwell patients.  There was a moderate correlation of 0.50 between 
4 Centor score and prescribing rate in the sore throat dataset.  
5
























8 At the individual level, more severely ill patients are more likely to receive a prescription with 
9 90.7% of those with a Centor score of 3+ receiving an immediate antibiotic (Table 2).  But 
10 prescribing levels for those will low severity scores was also high – 29.5% of sore throat patients 
11 with a Centor score 0 or 1 received a prescription.  For those with a Centor score of 2, the 
12 probability of receiving a prescription was almost 50/50.  
13
14 Table S1 Proportion receiving immediate antibiotics by Centor score
Centor scoreReceived immediate 
antibiotics
0/1 2 3/4
No 2,147 (70.5%) 1,501 (50.7)% 278 (9.3%)
Yes 900 (29.5%) 1,460 (49.3)% 2,721 (90.7%)
15
16 The MOR was 2.56 (95% credible interval 2.26, 2.94) when the model included the Centor score.  
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